Development of Good Manufacturing Practice-Compatible Isolation and Culture Methods for Human Olfactory...

Area of Science:

• Neuroscience
• Regenerative Medicine
• Cell Therapy

Background:

• Demyelination in the central nervous system (CNS) leads to nerve dysfunction and paralysis.
• Cell therapies, particularly mesenchymal stromal cells (MSCs), are explored for promoting remyelination.
• Human olfactory mucosa-derived MSCs (hOM-MSCs) demonstrated superior myelination potential compared to bone marrow-derived MSCs (hBM-MSCs).

Purpose of the Study:

• To develop a Good Manufacturing Practice (GMP)-compliant method for isolating and expanding hOM-MSCs for clinical applications.
• To assess the characteristics and pro-myelinating capacity of GMP-compliant hOM-MSCs.
• To evaluate the in vivo efficacy of GMP-compliant hOM-MSCs in a model of demyelinating disease.

Main Methods:

• hOM-MSCs were isolated and expanded using GMP-compliant media without enzymatic digestion, cell sorting, or antibiotics.
• Characterization included assessment of MSC surface markers and CXCL12 production.
• Pro-myelinating activity was evaluated in vitro using rodent CNS cultures.
• In vivo efficacy was tested using an experimental autoimmune encephalitis (EAE) model.

Main Results:

• GMP-compliant hOM-MSCs were successfully derived and expanded, expressing typical MSC markers.
• These cells robustly produced CXCL12 and demonstrated pro-myelinating effects in vitro, comparable to non-GMP cells.
• In the EAE model, GMP-compliant hOM-MSCs did not significantly improve disease scores compared to controls.

Conclusions:

• A GMP-compliant method for hOM-MSC derivation and expansion was established.
• GMP-compliant hOM-MSCs retain in vitro pro-myelinating capabilities.
• Further pre-clinical evaluation is essential to determine the in vivo therapeutic potential of GMP-compliant hOM-MSCs for demyelinating CNS diseases before clinical trials.